Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5048) 5048
Book Review (813) 813
Publication (544) 544
Newsletter (18) 18
Book Chapter (12) 12
Conference Proceeding (9) 9
Dissertation (3) 3
Magazine Article (3) 3
Data Set (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (4733) 4733
animals (3014) 3014
humans (2823) 2823
mice (2495) 2495
female (1920) 1920
immunology (1891) 1891
interleukin-12 (1422) 1422
male (1355) 1355
cytokines (1018) 1018
dendritic cells (940) 940
mice, inbred balb c (887) 887
mice, inbred c57bl (869) 869
interleukin-12 - metabolism (824) 824
interleukin-12 - immunology (817) 817
interleukin-12 - genetics (790) 790
il-12 (778) 778
immunotherapy (757) 757
t-cells (694) 694
adult (691) 691
medicine, research & experimental (681) 681
oncology (666) 666
in-vivo (637) 637
interleukin-12 - therapeutic use (636) 636
middle aged (621) 621
expression (607) 607
dendritic cells - immunology (591) 591
cancer (584) 584
cells, cultured (580) 580
interferon-gamma (578) 578
interleukin-12 - biosynthesis (567) 567
ifn-gamma (532) 532
pharmacology & pharmacy (492) 492
inflammation (461) 461
lymphocytes (455) 455
interleukin-12/23 monoclonal-antibody (451) 451
health aspects (447) 447
cytokine (445) 445
double-blind (441) 441
t cells (440) 440
abridged index medicus (433) 433
disease models, animal (424) 424
psoriasis (423) 423
research (414) 414
th1 cells - immunology (414) 414
analysis (407) 407
cell biology (398) 398
interleukins (390) 390
interleukin 12 (385) 385
cells (377) 377
activation (374) 374
t-lymphocytes - immunology (368) 368
interferon-gamma - biosynthesis (366) 366
care and treatment (364) 364
cell line, tumor (362) 362
dermatology (358) 358
immunity (357) 357
interferon-gamma - metabolism (353) 353
antibodies, monoclonal - therapeutic use (339) 339
macrophages (327) 327
biochemistry & molecular biology (326) 326
immune response (325) 325
treatment outcome (324) 324
aged (321) 321
biotechnology & applied microbiology (321) 321
gene expression (313) 313
psoriasis - drug therapy (311) 311
enzyme-linked immunosorbent assay (309) 309
interleukin-12 - blood (304) 304
interleukin-12 - pharmacology (304) 304
flow cytometry (300) 300
therapy (298) 298
induction (297) 297
vaccination (293) 293
interferon-gamma - immunology (292) 292
tumors (288) 288
research article (286) 286
ustekinumab (285) 285
killer cells, natural - immunology (283) 283
mice, knockout (278) 278
antigens (277) 277
immune system (277) 277
time factors (277) 277
gene therapy (276) 276
article (272) 272
immune-responses (266) 266
vaccines (266) 266
medicine (263) 263
responses (259) 259
infection (256) 256
proteins (249) 249
rodents (249) 249
in-vitro (247) 247
tumor-necrosis-factor (244) 244
dendritic cells - drug effects (241) 241
cd8-positive t-lymphocytes - immunology (239) 239
dendritic cells - metabolism (238) 238
genetics & heredity (235) 235
cytokines - biosynthesis (233) 233
cytokines - metabolism (230) 230
interleukin-12 - administration & dosage (229) 229
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4955) 4955
Chinese (48) 48
Japanese (26) 26
Spanish (10) 10
Polish (8) 8
German (7) 7
French (5) 5
Russian (4) 4
Turkish (3) 3
Portuguese (2) 2
Danish (1) 1
Finnish (1) 1
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
by Ritchlin, Christopher and Rahman, Proton and Kavanaugh, Arthur and McInnes, Iain B and Puig, Lluis and Li, Shu and Wang, Yuhua and Shen, Yaung-Kaung and Doyle, Mittie K and Mendelsohn, Alan M and Gottlieb, Alice B and PSUMMIT 2 Study Grp and PSUMMIT 2 Study Group and on behalf of the PSUMMIT 2 Study Group
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2014, Volume 73, Issue 6, pp. 990 - 999
Objective Assess ustekinumab efficacy (week 24/week 52) and safety (week 16/week 24/week 60) in patients with active psoriatic arthritis (PsA) despite... 
RHEUMATOID-ARTHRITIS | MORTALITY | CRITERIA | TO-SEVERE PSORIASIS | CLINICAL-TRIALS | VALIDATION | IMPROVEMENT | DEATH | RHEUMATOLOGY | ETANERCEPT | DISEASE-ACTIVITY | Certolizumab Pegol | Humans | Middle Aged | Ustekinumab | Antibodies, Monoclonal - therapeutic use | Male | Immunoglobulin Fab Fragments - therapeutic use | Methotrexate - therapeutic use | Polyethylene Glycols - therapeutic use | Interleukin-12 Subunit p40 - antagonists & inhibitors | Receptors, Tumor Necrosis Factor - therapeutic use | Etanercept | Infliximab | Arthritis, Psoriatic - drug therapy | Treatment Failure | Adult | Female | Antirheumatic Agents - therapeutic use | Severity of Illness Index | Antibodies, Monoclonal, Humanized - therapeutic use | Psoriasis - drug therapy | Double-Blind Method | Immunoglobulin G - therapeutic use | Treatment Outcome | Cross-Over Studies | Adalimumab | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Clinical trials | Care and treatment | Usage | Psoriatic arthritis | Heart attacks | Tuberculosis | Psoriasis | Mortality | Response rates | Gangrene | Tumor necrosis factor-TNF | Arthritis | Pharmaceutical industry | Drug dosages | Quality of life | Index Medicus | Anti-TNF | Clinical and Epidemiological Research | 1506 | Spondyloarthritis | Psoriatic Arthritis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
by Bachelez, Hervé, Prof and van de Kerkhof, Peter C M, Prof and Strohal, Robert, Prof and Kubanov, Alexey, Prof and Valenzuela, Fernando, MD and Lee, Joo-Heung, Prof and Yakusevich, Vladimir, Prof and Chimenti, Sergio, Prof and Papacharalambous, Jocelyne, MD and Proulx, James, MD and Gupta, Pankaj, PhD and Tan, Huaming, PhD and Tawadrous, Margaret, MD and Valdez, Hernan, MD and Wolk, Robert, MD and OPT Compare Investigators
Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 9993, pp. 552 - 561
Summary Background New therapeutic options are needed for patients with psoriasis. Tofacitinib, an oral Janus kinase inhibitor, is being investigated as a... 
Internal Medicine | RHEUMATOID-ARTHRITIS | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | EFFICACY | SAFETY | JANUS KINASE INHIBITOR | DOUBLE-BLIND | METHOTREXATE | PATIENT | INTERLEUKIN-12/23 MONOCLONAL-ANTIBODY | CP-690,550 | Psoriasis - drug therapy | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Immunoglobulin G - therapeutic use | Male | Treatment Outcome | Receptors, Tumor Necrosis Factor - therapeutic use | Dose-Response Relationship, Drug | Etanercept | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Adult | Female | Pyrroles - therapeutic use | Chronic Disease | Psoriasis | Medical colleges | Cytokines | Pathogenesis | Tumor necrosis factor-TNF | FDA approval | Drug therapy | Drug dosages | Patients | Index Medicus | Abridged Index Medicus | Anti-Inflammatory Agents, Non-Steroidal | Dermatology | Immunoglobulin G | Pyrroles | Life Sciences | Human health and pathology | Protein Kinase Inhibitors | Pyrimidines | Receptors, Tumor Necrosis Factor | Piperidines
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
by Griffiths, Christopher E.M and Strober, Bruce E and van de Kerkhof, Peter and Ho, Vincent and Fidelus-Gort, Roseanne and Yeilding, Newman and Guzzo, Cynthia and Xia, Yichuan and Zhou, Bei and Li, Shu and Dooley, Lisa T and Goldstein, Neil H and Menter, Alan and ACCEPT Study Grp and ACCEPT Study Group
The New England Journal of Medicine, ISSN 0028-4793, 01/2010, Volume 362, Issue 2, pp. 118 - 128
In this 12-week randomized trial comparing two biologic agents known to be effective for psoriasis, ustekinumab (an interleukin-12 and interleukin-23 blocker)... 
RANDOMIZED-CONTROLLED-TRIAL | MEDICINE, GENERAL & INTERNAL | PLACEBO | CHRONIC PLAQUE PSORIASIS | EFFICACY | SAFETY | DOUBLE-BLIND | METHOTREXATE | TNF INHIBITION | INDUCTION | INTERLEUKIN-12/23 MONOCLONAL-ANTIBODY | Severity of Illness Index | Psoriasis - drug therapy | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Immunologic Factors - administration & dosage | Immunoglobulin G - therapeutic use | Ustekinumab | Antibodies, Monoclonal - therapeutic use | Male | Receptors, Tumor Necrosis Factor - administration & dosage | Immunoglobulin G - administration & dosage | Receptors, Tumor Necrosis Factor - therapeutic use | Antibodies, Monoclonal, Humanized | Etanercept | Antibodies, Monoclonal - administration & dosage | Interleukin-23 - antagonists & inhibitors | Interleukin-12 - antagonists & inhibitors | Adult | Female | Immunosuppressive Agents - administration & dosage | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Immunologic Factors - therapeutic use | Dosage and administration | Psoriasis | Comparative analysis | Drug therapy | Fees & charges | Cytokines | Stock options | Laboratories | Research & development--R&D | Equity | Interleukin 23 | Interleukin 12 | Tumor necrosis factor-α | Light therapy | Patients | Studies | Tumor necrosis factor-TNF | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics
by Menter, Alan and Gottlieb, Alice and Feldman, Steven R and Van Voorhees, Abby S and Leonardi, Craig L and Gordon, Kenneth B and Lebwohl, Mark and Koo, John Y.M and Elmets, Craig A and Korman, Neil J and Beutner, Karl R and Bhushan, Reva
Journal of the American Academy of Dermatology, ISSN 0190-9622, 05/2008, Volume 58, Issue 5, pp. 826 - 850
Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the... 
PHASE-III TRIAL | CHRONIC PLAQUE PSORIASIS | INTEGRATED MULTISTUDY DATABASE | CONTINUOUS EFALIZUMAB THERAPY | SQUAMOUS-CELL CARCINOMA | POPULATION-BASED COHORT | NECROSIS-FACTOR-ALPHA | QUALITY-OF-LIFE | RANDOMIZED CONTROLLED-TRIAL | PLACEBO-CONTROLLED TRIAL | DERMATOLOGY | Smoking - adverse effects | Cardiovascular Diseases - etiology | Psoriasis - drug therapy | Obesity - complications | Humans | Recombinant Fusion Proteins - therapeutic use | Antibodies, Monoclonal - therapeutic use | Metabolic Syndrome - complications | Immunoglobulin G - adverse effects | Psoriasis - complications | Depression - etiology | Cyclosporine - therapeutic use | Methotrexate - adverse effects | Etanercept | Lymphoma - etiology | Receptors, Tumor Necrosis Factor | Interleukin-23 - antagonists & inhibitors | PUVA Therapy | Arthritis, Psoriatic - drug therapy | Interleukin-12 - antagonists & inhibitors | Acitretin - adverse effects | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Biological Products - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Biologic drug survival in Israeli psoriasis patients
by Shalom, Guy, MD, MHA and Cohen, Arnon D., MD, MPH, PhD and Ziv, Michael, MD and Eran, Cohen Barak, MD and Feldhamer, Ilan, MsC and Freud, Tamar, MHA, PhD and Berman, Eitan, MD and Oren, Shirley, MD and Hodak, Emmilia, MD and Pavlovsky, Lev, MD, PhD
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2016, Volume 76, Issue 4, pp. 662 - 669.e1
Background Drug survival is defined as the time period of treatment with a certain drug until its cessation. The role of previous exposure to traditional... 
Dermatology | ustekinumab | etanercept | infliximab | psoriasis | biologic medications | drug survival | adalimumab | ADHERENCE | DISCONTINUATION | DERMATOLOGY | RATES | IMMUNOGENICITY | INTERVENTIONS | CONSEQUENCES | AGENTS | VULGARIS | REGISTRY | Etanercept - administration & dosage | Dermatologic Agents - administration & dosage | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Dermatologic Agents - therapeutic use | Methotrexate - therapeutic use | Infliximab - therapeutic use | Infliximab - administration & dosage | Psoriasis - complications | Time Factors | Adult | Female | Acitretin - therapeutic use | Drug Therapy, Combination | Ustekinumab - administration & dosage | Immunosuppressive Agents - administration & dosage | Interleukin-12 Receptor beta 1 Subunit - antagonists & inhibitors | Databases, Factual | Psoriasis - drug therapy | Drug Tolerance | Ustekinumab - therapeutic use | Metabolic Syndrome - complications | Adalimumab - therapeutic use | Adalimumab - administration & dosage | Israel | Drug Substitution | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Etanercept - therapeutic use | Psoriasis | Patient outcomes | Formulae, receipts, prescriptions | Medical care | Family medicine | Dermatologic agents | Drug therapy | Quality management | Beer | Analysis | Retinoids | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
by Blauvelt, Andrew, MD, MBA and Reich, Kristian, MD and Tsai, Tsen-Fang, MD and Tyring, Stephen, MD, PhD and Vanaclocha, Francisco, MD and Kingo, Külli, MD, PhD and Ziv, Michael, MD, BSc and Pinter, Andreas, MD and Vender, Ronald, MD, FRCPC and Hugot, Sophie, MSc and You, Ruquan, MSc and Milutinovic, Marina, MD and Thaçi, Diamant, MD
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2016, Volume 76, Issue 1, pp. 60 - 69.e9
Background Secukinumab demonstrated superior efficacy to ustekinumab at week 4 and week 16 of the CLEAR study, with comparable safety, in subjects with... 
Dermatology | clinical trial | ustekinumab | psoriasis | safety | secukinumab | Psoriasis Area and Severity Index (PASI) | efficacy | CONTROLLED-TRIAL | FUTURE | ARTHRITIS | INTERLEUKIN-12/23 MONOCLONAL-ANTIBODY | DERMATOLOGY | DOUBLE-BLIND | USABILITY | Severity of Illness Index | Psoriasis - drug therapy | Double-Blind Method | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Treatment Outcome | Dermatologic Agents - therapeutic use | Dermatologic Agents - adverse effects | Ustekinumab - therapeutic use | Ustekinumab - adverse effects | Adult | Female | Skin | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Generating hypotheses by discovering implicit associations in the literature: A case report of a search for new potential therapeutic uses for thalidomide
by Weeber, Marc and Vos, Rein and Klein, Henny and De Jong-Van Den Berg, Lolkje T. W and Aronson, Alan R and Molema, Grietje
Journal of the American Medical Informatics Association, ISSN 1067-5027, 05/2003, Volume 10, Issue 3, pp. 252 - 259
The availability of scientific bibliographies through online databases provides a rich source of information for scientists to support their research. However,... 
VIRUS-INFECTION | MEDICAL INFORMATICS | MESSENGER-RNA EXPRESSION | CHRONIC HEPATITIS-C | MONONUCLEAR-CELLS | COMPUTER SCIENCE, INFORMATION SYSTEMS | NECROSIS-FACTOR-ALPHA | COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS | CYTOKINE PRODUCTION | MULTIPLE-SCLEROSIS | HEALTH CARE SCIENCES & SERVICES | INFORMATION SCIENCE & LIBRARY SCIENCE | TNF-ALPHA | ACUTE-PANCREATITIS | MYASTHENIA-GRAVIS | Unified Medical Language System | Information Storage and Retrieval - methods | Humans | Interleukin-12 - antagonists & inhibitors | Natural Language Processing | Thalidomide - immunology | Databases, Bibliographic | Thalidomide - therapeutic use | PubMed | thalidomide | Index Medicus | Original Investigation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
by Routy, Bertrand and Le Chatelier, Emmanuelle and Derosa, Lisa and Duong, Connie P.M and Alou, Maryam Tidjani and Daillère, Romain and Fluckiger, Aurélie and Messaoudene, Meriem and Rauber, Conrad and Roberti, Maria P and Fidelle, Marine and Flament, Caroline and Poirier-Colame, Vichnou and Opolon, Paule and Klein, Christophe and Iribarren, Kristina and Mondragón, Laura and Jacquelot, Nicolas and Qu, Bo and Ferrere, Gladys and Clémenson, Céline and Mezquita, Laura and Masip, Jordi Remon and Naltet, Charles and Brosseau, Solenn and Kaderbhai, Coureche and Richard, Corentin and Rizvi, Hira and Levenez, Florence and Galleron, Nathalie and Quinquis, Benoit and Pons, Nicolas and Ryffel, Bernhard and Minard-Colin, Véronique and Gonin, Patrick and Soria, Jean-Charles and Deutsch, Eric and Loriot, Yohann and Ghiringhelli, François and Zalcman, Gérard and Goldwasser, François and Escudier, Bernard and Hellmann, Matthew D and Eggermont, Alexander and Raoult, Didier and Albiges, Laurence and Kroemer, Guido and Zitvogel, Laurence
Science, ISSN 0036-8075, 01/2018, Volume 359, Issue 6371, pp. 91 - 97
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis induce sustained clinical responses in a sizable minority of cancer patients. We found that... 
CELL LUNG-CANCER | MELANOMA | MICROENVIRONMENT | INTESTINAL MICROBIOTA | CYCLOPHOSPHAMIDE | PD-1 BLOCKADE | MULTIDISCIPLINARY SCIENCES | GENES | RESISTANCE | ANTITUMOR IMMUNITY | NIVOLUMAB | CD4 Antigens - immunology | Immunotherapy - methods | Humans | Antibodies, Monoclonal - therapeutic use | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Gastrointestinal Microbiome - genetics | Fecal Microbiota Transplantation | Anti-Bacterial Agents - therapeutic use | Feces - microbiology | Metagenome - genetics | Neoplasms - therapy | Animals | Receptors, CCR - immunology | Interleukin-12 - immunology | Receptors, CXCR3 - immunology | T-Lymphocytes - immunology | Mice | Gastrointestinal Microbiome - immunology | Verrucomicrobia - genetics | Verrucomicrobia - immunology | Care and treatment | Cell receptors | Microbiota (Symbiotic organisms) | Immunotherapy | Epithelial tumors | Physiological aspects | Health aspects | Methods | Apoptosis | PD-1 protein | Lung | Interleukin | Microbiomes | Transplantation | Lymphocytes T | Anticancer properties | Microbiota | Lymphocytes | Bacteria | Feces | Supplementation | Gnotobiotics | Kidneys | Melanoma | Dietary supplements | Interleukin 12 | Abundance | CXCR3 protein | Patients | CD4 antigen | Immune checkpoint | Antibiotics | Flora | PD-L1 protein | Relative abundance | Antitumor activity | CCR9 protein | Tumors | Kidney transplantation | Cancer | Index Medicus | Life Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events: A Meta-analysis of Randomized Controlled Trials
by Ryan, Caitriona and Leonardi, Craig L and Krueger, James G and Kimball, Alexa B and Strober, Bruce E and Gordon, Kenneth B and Langley, Richard G and de Lemos, James A and Daoud, Yahya and Blankenship, Derek and Kazi, Salahuddin and Kaplan, Daniel H and Friedewald, Vincent E and Menter, Alan
JAMA, ISSN 0098-7484, 08/2011, Volume 306, Issue 8, pp. 864 - 871
CONTEXT Ustekinumab and briakinumab, monoclonal antibodies to the shared p40 subunit of interleukin (IL)-12 and IL-23, have shown efficacy in treating chronic... 
MODERATE | MEDICINE, GENERAL & INTERNAL | MONOTHERAPY | EFFICACY | SAFETY | USTEKINUMAB | PHASE-III | INFLIXIMAB INDUCTION | DOUBLE-BLIND | ETANERCEPT | INTERLEUKIN-12/23 MONOCLONAL-ANTIBODY | Myocardial Infarction - chemically induced | Humans | Interleukin-23 | Middle Aged | Antibodies, Monoclonal - adverse effects | Ustekinumab | Antibodies, Monoclonal - therapeutic use | Risk | Receptors, Tumor Necrosis Factor - therapeutic use | Young Adult | Antibodies, Monoclonal, Humanized | Stroke - chemically induced | Etanercept | Infliximab | Placebos | Adult | Psoriasis - drug therapy | Double-Blind Method | Interleukin-12 | Immunoglobulin G - therapeutic use | Tumor Necrosis Factor-alpha | Immunoglobulin G - adverse effects | Randomized Controlled Trials as Topic | Adolescent | Aged | Cardiovascular Diseases - chemically induced | Immunologic Factors - adverse effects | Adalimumab | Immunologic Factors - therapeutic use | Usage | Psoriasis | Cardiovascular diseases | Drug therapy | Health aspects | Risk factors | Meta-analysis | Cardiovascular disease | Side effects | Biological products | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
by Papp, Kim A and Blauvelt, Andrew and Bukhalo, Michael and Gooderham, Melinda and Krueger, James and Lacour, Jean-Philippe and Menter, Alan and Philipp, Sandra and Sofen, Howard and Tyring, Stephen and Berner, Beate R and Visvanathan, Sudha and Pamulapati, Chandrasena and Bennett, Nathan and Flack, Mary and Scholl, Paul and Padula, Steven J
The New England Journal of Medicine, ISSN 0028-4793, 04/2017, Volume 376, Issue 16, pp. 1551 - 1560
In a phase 2 trial involving 166 patients with moderate-to-severe plaque psoriasis, risankizumab, a humanized monoclonal antibody that selectively inhibits... 
POPULATION | MEDICINE, GENERAL & INTERNAL | EFFICACY | SAFETY | CLINICAL-TRIALS | DOUBLE-BLIND | COMMON | MECHANISMS | PLACEBO-CONTROLLED TRIAL | IL-23 | Severity of Illness Index | Psoriasis - drug therapy | Double-Blind Method | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Kaplan-Meier Estimate | Antibodies, Monoclonal - therapeutic use | Male | Dermatologic Agents - therapeutic use | Dermatologic Agents - adverse effects | Ustekinumab - therapeutic use | Ustekinumab - adverse effects | Scalp - pathology | Interleukin-23 - antagonists & inhibitors | Interleukin-12 - antagonists & inhibitors | Adult | Female | Psoriasis - classification | Aged | Treatment outcome | Psoriasis | Patient outcomes | Monoclonal antibodies | Dosage and administration | Drug therapy | Comparative analysis | Carcinoma | Cytokines | Immunoglobulin G | Body weight | Interleukin 23 | Interleukin 12 | FDA approval | Light therapy | TNF inhibitors | Tumor necrosis factor-TNF | Skin | Pharmaceutical industry | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials
by Kavanaugh, Arthur and Ritchlin, Christopher and Rahman, Proton and Puig, Lluis and Gottlieb, Alice B and Li, Shu and Wang, Yuhua and Noonan, Lenore and Brodmerkel, Carrie and Song, Michael and Mendelsohn, Alan M and McInnes, Iain B and PSUMMIT-2 Study Grp and PSUMMIT-1 Study Grp and PSUMMIT-1 and 2 Study Groups and on behalf of the PSUMMIT-1 and 2 Study Groups
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2014, Volume 73, Issue 6, pp. 1000 - 1006
Objective Evaluate ustekinumab, an anti-interleukin (IL)-12 and IL-23 antibody, effects on radiographic progression in psoriatic arthritis (PsA). Methods We... 
BODY-MASS | RHEUMATOLOGY | EFFICACY | ETANERCEPT | SAFETY | JOINT DAMAGE | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Foot Joints - diagnostic imaging | Humans | Middle Aged | Ustekinumab | Male | Treatment Outcome | Methotrexate - therapeutic use | Disease Progression | Interleukin-12 Subunit p40 - antagonists & inhibitors | Cross-Over Studies | Radiography | Arthritis, Psoriatic - diagnostic imaging | Arthritis, Psoriatic - drug therapy | Hand Joints - diagnostic imaging | Adult | Female | Drug Therapy, Combination | Antirheumatic Agents - therapeutic use | Clinical trials | Care and treatment | Usage | Psoriatic arthritis | Studies | Psoriasis | Cytokines | Research & development--R&D | Index Medicus | Anti-TNF | Clinical and Epidemiological Research | 1506 | Spondyloarthritis | Psoriatic Arthritis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights